NCT06687772View on ClinicalTrials.gov

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Thiotepa

Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.

DRUG

Carmustine

Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.

PROCEDURE

Autologous Stem Cell Transplant

Infusion of autologous peripheral blood stem cells on Day 0.

DRUG

Anthracycline-based induction chemotherapy

Standard of care, not dictated by protocol.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER